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BiomarkerThe objective of this study was to investigate the catalytic activity of basic aminopeptidase (APB) and its
association with periarticular edema and circulating tumor necrosis factor (TNF)-alpha and type II collagen
(CII) antibodies (AACII) in a rat model of rheumatoid arthritis (RA) induced by CII (CIA). Edema does not occur
in part of CII-treated, even when AACII is higher than in control. TNF-alpha is detectable only in edematous
CII-treated. APB in synovial membrane is predominantly a membrane-bound activity also present in soluble
form and with higher activity in edematous than in non-edematous CII-treated or control. Synovial ﬂuid and
blood plasma have lower APB in non-edematous than in edematous CII-treated or control. In peripheral blood
mononuclear cells (PBMCs) the highest levels of APB are found in soluble form in control and in membrane-
bound form in non-edematous CII-treated. CII treatment distinguishes two categories of rats: one with
arthritic edema, high AACII, detectable TNF-alpha, high soluble and membrane-bound APB in synovial
membrane and low APB in the soluble fraction of PBMCs, and another without edema and with high AACII,
undetectable TNF-alpha, low APB in the synovial ﬂuid and blood plasma and high APB in the membrane-
bound fraction of PBMCs. Data suggest that APB and CIA are strongly related.; Ang, angiotensin; APB, basic
pe II collagen; CIA, collagen-
otriene-A4; LTA4H, leukotriene
tinamide adenine dinucleotide,
cells; PGP, Pro-Gly-Pro; RA,
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Rheumatoid arthritis (RA) is an inﬂammatory, chronic, systemic
and autoimmune disease [1,2] of unknown etiology [1–4] that affects
about 1% of the world's population [1,2,5]. It is associated with
increased mortality and signiﬁcant comorbidities and other factors
that can speciﬁcally affect a patient's quality of life [6,7]. The
prominent characteristic of RA is a symmetrical peripheral polyar-
thritis with bone erosions, mainly of cartilage, and resultant deformity
and joint destruction [8]. This process is associated with inﬂammatory
hyperplasia of the synovial membrane, also known as pannus [9], and
pathological neovascularization, which occur after the inﬁltration of
inﬂammatory cells into the synovial membranes [10], as well as an
immune response against cartilage components, among them the
type II collagen (CII) has been thought to be the most usual [8]. Tumor
necrosis factor (TNF)-alpha has also been found in high concentra-
tions in the serum and synovial ﬂuid of RA patients [1,10].The genetic predisposition linked to human leukocyte antigen
system has been estimated to contribute with about 50% or less for
the development of disease [11]. Thus, several epigenetic factors
appear to be involved in the onset of RA, such as DNA methylation,
alternative splicing, micro RNAs and histone modiﬁcations [11].
Moreover, factors such as infections, smoking, pregnancy, sex
hormones and others may lead to autoimmunity [4]. CII is
considered the primary antigen in RA, since it is themain constituent
of cartilage [2] and because antibodies anti-CII (AACII) have been
detected in synovial ﬂuid [5,12], cartilage and B cells present in the
synovial membrane of arthritic patients [12]. Furthermore, mani-
festations of RA have close similarity with those of the experimental
model of CII-induced arthritis (CIA), that are: synovitis, progressive
pannus formation, marginal erosion of bone and cartilage destruc-
tion [5,12,13]. The transfer of AACII is also able to induce RA, because
these antibodies bind to normal cartilage and activate the comple-
ment system [5]. In the CIA model, symptoms of RA begin about
21 days after the injection of CII [13]. According to Stuart et al. [9],
the initial lesion observed in this experimental model of RA is ﬁbrin
deposition in the synovial membrane 5 days after immunization. On
the 12th day there is an intense deposition of ﬁbrin and tissue
hyperplasia. On the 19th day the inﬁltration of mononuclear and
polymorphonuclear cells begins. Inﬂammation occurs so rapidly that
the destruction of cartilage and the marginal erosion of the bone
occur in a few days [9].
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and other proteins implicated in matrix degradation, cell activation,
inﬂammation and bone collagen degradation products accompany
early rheumatoid and osteoarthritis development and can precede the
canonical diagnostic detection by several years [14,15], as well as that
CD13, an aminopeptidase type enzyme, was histologically expressed
strongly in RA synovial tissue lining cells [16], it can be hypothesized
that changes of other aminopeptidase hydrolytic activities, such as the
basic aminopeptidase (APB) activity, could be important in RA, mainly
because APB activity was reported to be increased in the soluble
fraction of elicited macrophages [17] and because kallidin [18],
leukotriene(LT)-A4 [19,20] and angiotensin (Ang) III [21], three of the
known natural substrates susceptible to hydrolysis by isozymes with
APB activity, have recognized actions in regulating angiogenesis [22]
and inﬂammation [23].
To prospect new markers and contribute to elucidate the etiology
of RA, this study aims to assess changes in the APB activity of blood
plasma, synovial ﬂuid and soluble (SF) and solubilized membrane-
bound (MF) fractions from the synovial membrane of the knee and
from peripheral blood mononuclear cells (PBMCs), associating this
enzyme activity with hind paw edema and with the AACII titer in
blood plasma and TNF-alpha levels in blood serum of control and CII-
treated rats.
2. Materials and methods
2.1. Animals, treatments and samples
Adult male Wistar rats, weighing 150–160 g, provided by the
Animal Facility of the Instituto Butantan, were maintained in
polyethylene cages (inside length×width×height=56×35×19 cm)
with food and tap water ad libitum, in a container with controlled
temperature of 25 °C, relative humidity of 65.3±0.9% and 12 h:12 h
photoperiod light:dark (lights on at 6:00 am). The animals and
research protocols used in this study are in agreementwith the COBEA
(Brazilian College of Animal Experimentation) and were approved by
the Ethics Committee of the Instituto Butantan (682/09).
The animals were anesthetized with a solution of ketamine
(Ketamine, Syntec, Cotia, São Paulo, Brazil) (3.75%) and xylazine
(Calmiun, Agener Union, Planalto Paulista, São Paulo, Brazil) (0.5%)
at a dose of 0.2 mL/100 g body weight, via intraperitoneal, and then
subjected to induction of arthritis by administration of CII from
chicken (Sigma, St. Louis, MO, USA) dissolved in 0.01 M acetic acid
and emulsiﬁed in an equal volume of Freund's incomplete adjuvant
(Sigma, St. Louis, MO, USA) (prepared at 4 °C just before use), via a
single intradermal dose of 0.4 mg/0.2 mL/animal, into the proximal
one-third of the tail (induced animals), or with 0.9% saline at the
same scheme of administration (sham induction). On day 41 after
treatment, the animals were anesthetized using the same scheme
speciﬁed above and the thickness of the hind paws were measured
in order to evaluate edema. Based on this measurement the
following experimental groups were formed: Control (all animals
submitted to sham induction); Arthritic (induced animals with hind
paw thickness N7 mm); Resistant (induced animals with hind paw
thickness similar to control). Thus, blood was withdrawn from the
left ventricle with heparinized and not heparinized syringes in
order to obtain plasma and serum, respectively. Heparinized blood
was centrifuged (at 200×g for 10 min at room temperature) to
separate plasma (supernatant) from the pellet containing PBMCs
and other blood cells. The non-heparinized blood was left at room
temperature for 10 min and then centrifuged under the same
conditions to obtain the serum. The synovial ﬂuid and synovial
membrane were subsequently removed from both knees of each
animal. The withdrawal of synovial ﬂuid and synovial membrane
was performed as follows: 200 μL of 0.9% NaCl was injected
intraarticularly into each knee and aspirated with a syringe and,after such washing, the synovial membrane was excised together
with the connective tissue of the joint capsule.
2.2. Separation of PBMCs
According to the method of Maldonado and Curi [24] with
modiﬁcations as follow: the pellet resulting from the obtainment of
blood plasma was reconstituted to the original volume with 0.9%
NaCl and then carefully layered on equal volume of Percoll
(ρ=1.077 mg/mL) (GE-Healthcare) and subsequently centrifuged
(200×g for 20 min at room temperature). The layer containing the
PBMCs was then removed from the tube and washed twice with 0.9%
NaCl (1:3 v/v diluted blood cells) and centrifuged again at the same
conditions to discard the supernatant.
2.3. Cell counting and viability
PBMCs were resuspended in 0.5 mL of 0.9% NaCl. The total number
of PBMCs was assessed in 20 μL aliquots of this suspension diluted
with Turk's ﬂuid (1:20, v/v). The cell viability was assessed using 40 μL
aliquots of this suspension diluted in equal volume of Trypan. Cell
counting was performed in a Neubauer chamber under optical
microscopy.
2.4. Evaluation of the canonical signs of RA
2.4.1. Paw edema
Hind paw swelling was quantiﬁed by macroscopic measurement
of the dorsal–plantar thickness of the hind paws in the region of the
metatarsus with a paquimeter (Mitutoyo, Aurora, IL, USA). Both paws
were measured and the average thickness was calculated for each
animal.
2.4.2. Molecular markers
AACII wasmeasured in blood plasma and TNF-alphawasmeasured
in blood serum with Enzyme-Linked ImmunoSorbent Assay (ELISA)
kits purchased from Chondrex (Redmond, WA, USA) and Biosource
(Carlsbad, CA, USA), respectively, according to the manufacturer's
recommendations.
2.5. Obtaining SF and MF from the synovial membranes and PBMCs
The synovial membranes from both knees of each animal were
homogenized in 10 mM Tris–HCl buffer, pH 7.4 (0.1 g tissue/3.0 mL)
for 3 min at 15,000 rpm (homogenizer Polytron-Aggregate, Kinema-
tica, Lucerne, Switzerland). PBMCs, resuspended in 0.9% NaCl, were
sonicated in 10 mMTris–HCl, pH 7.4 (3.0×106 cells/mL), for 10 s at an
amplitude level of 40 microm at a constant frequency of 20 KHz. These
samples were then ultracentrifuged at 100,000×g for 35 min
(ultracentrifuge Hitachi model CP60E). The resulting supernatants
correspond to SF. The resulting pellets were washed twice with the
same buffer and ultracentrifuged at 100,000×g for 35 min, to assure
the complete removal of SF. Subsequently, the pellet was homoge-
nized for 3 min at 800 rpm (homogenizer Tecnal TE 099, Tecnal,
Piracicaba, SP, Brazil) with the same volume of the same buffer plus
Triton X-100 (0.1%) and ultracentrifuged again (100,000×g for
35 min). The resulting supernatants correspond to MF. All procedures
were carried out at 4 °C.
As a marker for the fractionation procedure, lactate dehydrogenase
(LDH) activitywas determined, photometrically, at 340 nm, in SF andMF,
as previously described [25]. Brieﬂy, samples of 3 μL of SF and MF, in
triplicates, were incubated with 297 μL of 100 mM phosphate buffer, pH
7.4, containing 200 mM NaCl and 1.6 mM sodium pyruvate solution
(Sigma, St. Louis, MO, USA) and 0.2 mM nicotinamide adenine dinucle-
otide, reduced form (NADH) disodium salt (Sigma, St. Louis, MO, USA).
Twomeasurements of absorbance at 340 nmwere performed: the ﬁrst at
Table 1
Titer of antibodies anti-type II collagen (AAC-II) and levels of tumor necrosis factor
(TNF)-alpha in sham induced (control), CIA-treated that developed hind paw edema
(arthritic) and CIA-treated rats that did not develop hind paw edema (resistant).
Animals Blood plasma AAC-II Blood serum TNF-alpha
(μg/mL) (pg/mL)
Control 0.039±0.018 (2) b4 (2)
Arthritic 186±5.7 (3)⁎ 21.5±2.5 (3)⁎⁎
Resistant 191±1.5 (3)⁎ b4 (3)
Limit of detection of ELISA kit is 4 pg TNF-alpha/mL.
Values are means±SEM.
Number of animals in parentheses.
Analysis of variance ANOVA (pb0.001) with post-hoc Student–Newman–Keuls
multiple comparisons test.
⁎ pb0.001 vs control.
⁎⁎ pb0.001 vs control and vs resistant.
Fig. 1. Classiﬁcation of experimental animals based on the formation of edema. Control
group is sham induced, and arthritic and resistant groups are CII-treated. Values are
means±SEM. Number of animals in parentheses. Analysis of variance ANOVA
(pb0.0001) with post-hoc Student–Newman–Keuls multiple comparisons test:
*pb0.001 vs control and vs resistant.
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LDHactivity (mMoxidizedNADHmin−1mg protein−1)wereobtainedby
subtracting the values of the second from that of the ﬁrst reading, and
extrapolated by comparison with a standard curve of NADH.
2.6. Total protein
Total proteinwasmeasured photometrically (Bio-Tek PowerWave
XR spectrophotometer, Bio-Tek, Winooski, VT, USA), at 630 nm, in
triplicates of 40 μL of synovial ﬂuid, plasma (diluted 500-fold) and SF
(diluted 10-fold) and MF (diluted 2-fold) from the synovial
membrane and PBMCs by the method of Bradford [26], using a Bio-
Rad protein assay reagent (Hercules, CA, USA). Protein contents were
extrapolated by comparison with standard curves of bovine serum
albumin (BSA) in the same diluent.
2.7. APB activity
As previously described by Zambotti-Villela et al. [27], using 25 μL
individual samples of blood plasma (205 to 450 μg protein), and
synovial ﬂuid (12 to 49 μg protein) and the SF (2.8 to 20 μg protein)
and MF (2.6 to 15 μg protein) from the synovial membrane, and 50 μL
and 100 μL individual samples respectively of SF (22 to 72 μg protein)
and MF (13 to 44 μg protein) from PBMCs, on the basis of the amount
of β-naphthylamine (Sigma, St. Louis, MO, USA) released as a result of
the enzyme activity of samples incubated at 37 °C for 30 min in 96-
well ﬂat bottom microplates (Corning Inc., NY, USA) with prewarmed
substrate solution of 0.5 mM L-arginine β-naphthylamide (Sigma, St.
Louis, MO, USA) to a ﬁnal volume of 300 μL in 0.05 M phosphate
buffer, pH 6.5, with 150 mM NaCl, 0.02 mM puromycin (Sigma, St.
Louis, MO, USA) and 0.1 mg BSA/mL. β-Naphthylamine was estimated
ﬂuorometrically using the Bio-Tek FL600FA Microplate Fluorescence/
Absorbance Reader, at 460/40 nm emission wavelength and 360/
40 nm excitation wavelength. The value of incubates at zero time
(blank)was subtracted and the relative ﬂuorescence was converted to
picomoles of β-naphthylamine by comparison with a correspondent
standard curve. APB activity was expressed as picomoles of hydro-
lyzed substrate min−1mg protein−1.
2.8. Data analysis
Data are shown as mean±standard error of the mean (SEM) and
were analyzed statistically using the GraphPad Instat™ software
package. Regression analyses were performed to obtain standard
curves of protein, NADH and β-naphthylamine. Student's t-test was
performed to compare values of LDH between SF and MF. To
compare values among the control, arthritic and resistant groups
one-way analysis of variance (ANOVA) was performed, followed by
Student–Newman–Keuls multiple comparisons test when differ-
ences were detected. In all the calculations a minimum critical level
of Pb0.05 was set.
3. Results
3.1. Induction of arthritis
3.1.1. Development of paw edema
About 40% of the animals submitted to CII treatment did not
develop paw swelling. Fig. 1 shows the swelling developed by animals
“sensitive” to the treatment with CII relatively to the absence of
swelling in control (sham induction) and animals “insensitive” to the
treatment with CII.
3.1.2. Molecular markers
Table 1 shows that AACII titer in blood plasma of the CII-treated
animals that developed or not the edema was higher than that ofcontrol. Table 1 also shows that TNF-alpha levels in blood serum did
not differ between control and CII-treated animals without edema,
but these levels were higher in blood serum of CII-treated animals
with edema than in control.
3.2. Efﬁciency of synovial membrane fractionation
In all groups under study the LDH activity of the synovial
membrane was detected only in the SF (mean±SEM, control group,
n=8; 0.81±0.15, Pb0.0001, unpaired, two-side Student's t test); in
the MF this activity was null (control group, n=8). Qualitatively
similar results were obtained in the SF and MF from PBMCs of all
groups (data not shown).
3.3. APB activity
Fig. 2 shows that APB activity is strongly expressed in the MF
from the synovial membrane of all groups under study. APB activity
in the SF and MF from the synovial membrane was higher in CII-
treated animals with swollen paws (arthritic) than in control or CII-
treated that did not develop paw swelling (resistant). Resistant and
control animals had similar APB activity in the SF and MF from the
Fig. 2. APB activity of blood plasma, synovial ﬂuid and soluble (SF) and solubilized membrane-bound (MF) fractions of synovial membrane in sham induced (control), CII-treated
that developed hind paw edema (arthritic) and CII-treated rats that did not develop hind paw edema (resistant). Values are means±SEM. Number of animals in parentheses.
Analysis of variance ANOVA (synovial membrane-SF, p=0.0015; synovial membrane-MF, p=0.0192; synovial ﬂuid, p=0.0397; blood plasma, p=0.0159) with post-hoc Student–
Newman–Keuls multiple comparisons test: *pb0.05 vs other two groups.
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ﬂuid and blood plasma was lower in resistant than in control or
arthritic animals, while arthritic animals and control animals had
similar APB activity.Fig. 3. APB activity of soluble (SF) and solubilized membrane-bound (MF) fractions of PBMC
CII-treated rats that did not develop hind paw edema (resistant). Values are means±SEM.
with post-hoc Student–Newman–Keuls multiple comparisons test: *pb0.001 vs other twoFig. 3 shows that APB activity in the SF from PBMCs of control was
higher than in arthritic or resistant animals. On the other hand, APB
activity in the MF from PBMCs of resistant was higher than in control
or arthritic animals.s in sham induced (control), CII-treated that developed hind paw edema (arthritic) and
Number of animals in parentheses. Analysis of variance ANOVA (SF and MF, pb0.0001)
groups.
219M.T. Mendes et al. / Regulatory Peptides 167 (2011) 215–2214. Discussion
4.1. Edema, AACII and TNF-alpha
CIA in rats or mice is the most commonly used animal model to
evaluate approved and pending therapies or to investigate the
pathogenesis of RA. Based on the degree of hind paw swelling
(edema) formed 41 days after the treatment with CII emulsiﬁed in
Freund's incomplete adjuvant, the present study characterized the
existence of CII-treated animals susceptible or resistant to the
induction of RA. Edema of the paws is the main feature of RA induced
by CII and is commonly used as a parameter for evaluating the
presence of RA [13,28]. The incidence of RA (edema) was 44% and
100% in the methods of CIA used respectively by Trentham et al. [13]
and Cuzzocrea et al. [28], while in the present study was about 60%.
TNF-alpha has been considered a major proinﬂammatory cytokine in
RA [1,10], and the differences detected here in TNF-alpha levels in
serum among arthritic, resistant and control animals agree with this
rule. Both CII-treated with edema and without edema showed a high
AACII titer, which would be expected only in immunized animals with
intense edematous response [29]. However, altered AACII titer occurs
in several diseases [30] and as evidenced in the present study it could
not be considered a differential parameter for RA. The present study
describes for the ﬁrst time that a considerable proportion of CII-
treated animals with high AACII titer does not develop edema, a
ﬁnding that reinforces the multifactorial feature of RA triggering and
the hypothesis that CII, as a largemolecule, contains different epitopes
with different degrees of immunoreactivity for different antibodies,
and these antibodies for CII could be pathogenic and nonpathogenic
[30]. The distinction between these possible types of antibodies would
have great impact on the diagnosis and treatment of RA.
4.2. APB and the susceptibility and resistance to develop RA in the
CIA model
Some factors can interfere with the successful onset of macro-
scopic signs of RA in CIA models, such as the denaturation of collagen
during dissolution and differences in animal lineages used [31,32].
Obviously, the crucial question of medical interest is not related to the
discrimination of exogenous factors that can determine the efﬁciency
of the methods of induction, but the identiﬁcation of possible
endogenous determinants of resistance of certain animals to develop
RA induced by these methods. On the other hand, as pointed out by
Hegen et al. [33] the questions of which animal model is most
predictive of therapeutic efﬁcacy or has more pathophysiological
features of human RA commonly arise in data evaluation, and
obviously the study in several models can be more predictive than
the data from either model alone. In this sense, the model used in the
present study is very interesting because it showed that APB activity
can be an attractive diagnostic tool for the determination of the
outcome of RA, and that this catalytic activity can be also used to
estimate the susceptibility to develop RA.
4.3. Possible mechanisms generating the altered APB activity in the
CIA model
APB hydrolytic activity is known to be exhibited by the proteins EC
3.4.11.6 and leukotriene A4-hydrolase (LTA4H) (EC 3.3.2.6). The
present study focuses only on APB catalytic activity without the aim to
identify the protein(s) responsible for this activity. It is known that EC
3.4.11.6 preferentially hydrolyzes basic residues (arginine and lysine)
of the N-terminal of several peptides [19,34], being widely distributed
in various tissues as a monomeric protein with molecular weight of
72,300 kDa [19,34], comprising 649 amino acid residues, showing 33%
identity and 48% similarity with EC 3.3.2.6, and also exhibiting the
catalytic activity of LTA4H [19,20]. Inmost cells studied, the protein EC3.4.11.6 seems to be predominantly cytosolic and secreted, but it has
also been found to be associated with the membrane [18,19] and the
Golgi apparatus, possibly transiting from the endoplasmic reticulum
to the Golgi complex [18]. However, there is no description of
transmembrane domains in its structure, and one hypothesis is that it
interacts with a membrane receptor [19]. Intracellularly, the protein
EC 3.4.11.6 could be involved in antigen processing, because it is
present in the proteasome [35]. The peptides generated by protea-
some degradation are incorporated into the endoplasmic reticulum
where they bind to MHC II [35]. Moreover, many peptides in the
endoplasmic reticulum undergo cleavage of N-terminal residue [35]
and the protein EC 3.4.11.6 could also act in that compartment,
helping antigenic processing. On the other hand, the membrane-
associated APB could act on extracellular angiogenic peptides such as
kallidin [18] and Ang-III [21]. Pannus formation, in both RA and CIA, is
angiogenesis-dependent and it has been increasingly recognized that
peptides are part of a pathogenic mechanism that contributes to
autoimmune inﬂammation in RA [36].
In the present study, the highest expression of APB activity was
found in the membrane-bound fraction from the synovial membrane,
and this activity was also present in the membrane-bound fraction
from PBMCs after a successful fractionation of soluble andmembrane-
bound fractions from these samples, as demonstrated by LDH activity.
Thus, the present study is the ﬁrst one to analyze APB activity in these
separate fractions from the synovial membrane and PBMCs. A
question arised from this data is whether soluble APB activity in
synovial ﬂuid and blood plasma is derived from synovial membrane
and/or PBMCs. For another aminopeptidase, the dipeptidyl peptidase
IV, the mechanism of shedding from the cell surface to the plasma is
thought to be caused by plasma enzymes [37]. This question and the
pathophysiological signiﬁcance of APB activity, not only in the
membrane fraction but also in the soluble fraction from the synovial
membrane, soluble and membrane fractions of PBMCs and in synovial
ﬂuid and blood plasma need further studies to be elucidated. For
example, it is known that the APB activity of the protein EC 3.4.11.6
increases in the presence of physiological concentrations of chloride
[34]. It is also known that changes in the levels of LTA4 and LTB4
(the product of the catalytic action of the proteins EC 3.3.2.6 and EC
3.4.11.6 on LTA4) generate changes in the APB activity of the protein
EC 3.4.11.6 [15], but it is unclear whether there is a mutual inter-
ference of peptide and eicosanoid substrates in each of the catalytic
activities of the protein EC 3.4.11.6. Moreover, both of the catalytic
activities of the protein EC 3.3.2.6, that are epoxide hydrolase on LTA4
[20,38,39] and peptide hydrolase on L-arginine β-naphthylamide and
analogs [38–40], are inhibited by divalent cations and stimulated by
monovalent anions, including chloride [34,40,41], as similarly occur
with the protein EC 3.4.11.6 [34], thus complicating the distinction
between these two proteins. Furthermore, the protein EC 3.3.2.6
appears to suffer suicidal inactivation when it is exposed to its lipid
substrate LTA4 [34].4.4. Present signiﬁcance of altered APB activity in the CIA model
Although the present study does not help to distinguish whether
one or both proteins are responsible for APB activity, in an important
area of controversy it suggested that the balance of intracellular APB
in PBMCs (activity in the soluble fraction of these cells) is crucial in the
triggering of RA. Furthermore, the present study clearly demonstrated
that the detection of increased levels of this catalytic activity in the
soluble and membrane-bound fractions from the synovial membrane
could help to the diagnosis of RA, while the detection of decreased
levels of this catalytic activity in synovial ﬂuid and blood plasma, as
well as of increased levels in membrane-bound fractions from PBMCs
is a feature of resistance to develop RA with potential prognostic
implications.
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The role of polymorphisms in disease susceptibility is becoming
increasingly relevant for the perspective of current medical practice
[42]. Could a high stability of membrane-bound APB in the PBMCs and
the consequent reduction of its release in body ﬂuids be an individual
protective factor against RA? It seems an interesting question to be
further investigated. Recently, the neutrophil chemoattractant Pro-
Gly-Pro (PGP), a biomarker for chronic obstructive pulmonary
disease, was identiﬁed as one of the physiological substrates of the
aminopeptidase activity of LTA4H [43]. In acute neutrophil driven
inﬂammation, PGP was degraded by aminopeptidase activity, which
facilitated the resolution of inﬂammation, but in chronic obstructive
pulmonary disease, the inhibition of this aminopeptidase activity
could lead to the accumulation of PGP and neutrophils [43].4.6. Concluding remarks
The treatment with CII emulsiﬁed in Freund's incomplete adjuvant
leads the rats to develop arthritic edema, high AACII, detectable TNF-
alpha, high APB activity in the soluble andmembrane-bound fractions
from the synovial membrane and low APB in the soluble fraction of
PBMCs or, on the other hand, absence of edema, high AACII,
undetectable TNF-alpha, low APB in the synovial ﬂuid and blood
plasma and high APB in the membrane-bound fraction of PBMCs. Data
suggest that APB represents potentially a new marker of diagnosis (in
synovial membrane and soluble fraction from PBMCs) and/or
prognosis (in synovial ﬂuid, blood plasma and membrane-bound
fraction from PBMCs) of RA. Given these data we believe that APB
activity monitoring in RA patients at risk for or with existing joint pain
and/or inﬂammation could be a cheap, simple and effective means to
harness the clinical potential of this parameter for diagnosis and
prognosis of RA. These data also suggest that the inhibition of APB
activity in extracellular ﬂuids such as synovial ﬂuid and blood plasma
needs to be investigated as a potential strategy for therapeutic
intervention in RA.Acknowledgments
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